Trials / Completed
CompletedNCT00334945
Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23, a Known Phosphaturic Agent
Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23 (a Known Phosphaturic Agent)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 35 (actual)
- Sponsor
- University of Alabama at Birmingham · Academic / Other
- Sex
- All
- Age
- 3 Years – 14 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effect of growth hormone treatment on phosphorus levels in the body. Phosphorus is an important mineral for bone growth. It is well known that growth hormone treatment improves bone density and bone mineral content. The amount of phosphorus is maintained by the kidneys. Fibroblast Growth Factor 23 has recently been recognized to help kidneys control phosphate levels.
Detailed description
This study will compare Fibroblast Growth Factor 23 levels in children with and without growth hormone deficiency. Children with growth hormone deficiency will have levels taken before starting growth hormone replacement and after it has been initiated.
Conditions
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2010-06-01
- Completion
- 2011-08-01
- First posted
- 2006-06-08
- Last updated
- 2011-11-16
Source: ClinicalTrials.gov record NCT00334945. Inclusion in this directory is not an endorsement.